Product image of Mirabegron Heumann (Mirabegron) supplied by GNH India

Mirabegron Heumann

Active Ingredient:
Mirabegron
Origin:
EU

Mirabegron Heumann (Mirabegron)

Mirabegron, the active ingredient in Mirabegron Heumann, is a β3‑adrenergic receptor agonist presented as an oral dosage form for oral use. It treats overactive bladder symptoms, including urgency, frequency and urge urinary incontinence, in adult patients.

GNH India supplies Mirabegron Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent batch release, regulatory compliance, and responsive technical support throughout the supply chain.

Manufacturer / TM Owner

Heumann Pharma Gmbh & Co. Generica Kg

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Mirabegron is indicated for conditions within the overactive bladder disease spectrum, where it improves bladder function.
  • Overactive bladder: increases bladder capacity and reduces urgency episodes.
  • Urinary urgency: decreases the frequency of sudden urges to void.
  • Urge urinary incontinence: lowers the number of involuntary leakage episodes.

How It Works

  • Mirabegron selectively activates β3‑adrenergic receptors located on detrusor smooth muscle cells in the bladder. Stimulation of these receptors raises intracellular cyclic AMP, leading to relaxation of the detrusor muscle during the storage phase of the micturition cycle. This relaxation expands functional bladder capacity, diminishes involuntary contractions, and consequently reduces urgency, frequency and urge incontinence.

Side Effects

Commonly reported adverse reactions to Mirabegron are generally mild to moderate in intensity.

Common Side Effects

  • Hypertension: increase in blood pressure.
  • Headache: mild to moderate headache.
  • Nasopharyngitis: upper respiratory tract infection symptoms.
  • Urinary tract infection: symptoms of UTI.
  • Constipation: reduced bowel movements.
  • Dry mouth: decreased salivation.

Serious or Rare Side Effects

  • Urinary retention: difficulty emptying the bladder.
  • Severe hypertension: markedly elevated blood pressure.
  • Tachycardia: rapid heart rate.
  • Angioedema: swelling of face, lips or tongue.
  • Myocardial infarction: rare heart attack events.
  • Anaphylaxis: severe allergic reaction.

Precautions & Warnings

Before initiating Mirabegron therapy, clinicians should evaluate several safety considerations.

  • Assess cardiovascular status: monitor blood pressure and heart rate regularly.
  • Review renal function: adjust use in patients with severe renal impairment.
  • Evaluate concomitant medications: avoid strong CYP2D6 inhibitors that may increase exposure.
  • Use caution in uncontrolled hypertension: do not initiate if systolic BP >180 mmHg.
  • Monitor for urinary retention: assess post‑void residual volume during treatment.
  • Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Avoid Interactions

Mirabegron may interact with other medicines through metabolic pathways or additive pharmacodynamic effects.

Major Interactions (Avoid)

  • Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, quinidine): may increase Mirabegron exposure.
  • Co‑administration with other β3‑adrenergic agonists: risk of excessive detrusor relaxation.
  • Combined use with antihypertensive agents: additive blood pressure‑lowering effect.

Moderate Interactions (Monitor Closely)

  • Moderate CYP2D6 inhibitors (e.g., duloxetine, sertraline): may modestly raise levels.
  • Diuretics: may increase chance of urinary retention.
  • Anticholinergic medications: may diminish Mirabegron's efficacy on bladder symptoms.

Frequently Asked Questions

Mirabegron Heumann is prescribed to manage symptoms of overactive bladder, including urinary urgency, frequency, and urge urinary incontinence. By improving bladder storage capacity, it helps reduce the number of sudden urges to void and episodes of involuntary leakage in adult patients.

Mirabegron selectively stimulates β3‑adrenergic receptors on the detrusor muscle of the bladder. This activation raises cyclic AMP levels, causing the muscle to relax during the storage phase of the urinary cycle, thereby increasing bladder capacity and reducing involuntary contractions that trigger urgency.

The dose of Mirabegron is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for Mirabegron in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron belongs to a different drug class (β3‑adrenergic agonist) and does not carry the anticholinergic side‑effects such as dry mouth or constipation that are common with antimuscarinic agents. Clinical studies show comparable efficacy in reducing urgency, with a distinct safety profile that may be preferable for patients intolerant to antimuscarinics.

Store Mirabegron Heumann at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mirabegron is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, but patients should follow the specific instructions provided by their prescriber regarding timing and any dietary considerations.

Serious adverse events, although rare, include significant hypertension, urinary retention, tachycardia, angioedema, myocardial infarction and severe allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience sudden high blood pressure, difficulty urinating, rapid heartbeat, facial swelling or signs of an allergic reaction.

Mirabegron is contraindicated in patients with uncontrolled hypertension (systolic >180 mmHg or diastolic >120 mmHg) and in those who are hypersensitive to the active ingredient or any excipients. Caution is also advised for individuals with severe renal impairment or those taking strong CYP2D6 inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mirabegron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT